TY - JOUR
T1 - Rapid detection of gut microbial metabolite trimethylamine n-oxide for chronic kidney disease prevention
AU - Chang, Yu Chun
AU - Chu, Yi Hsuan
AU - Wang, Chien Cheng
AU - Wang, Chih Hsuan
AU - Tain, You Lin
AU - Yang, Hung Wei
N1 - Funding Information:
Funding: This work was financially supported by the Ministry of Science and Technology (MOST109-2221-E-110-006-MY3), Chang Gung Memorial Hospital, Kaohsiung (CMRPG8K0211), and National Sun Yat-sen University (109-03), Taiwan.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/9
Y1 - 2021/9
N2 - The gut microbiota plays a critical role in chronic kidney disease (CKD) and hypertension. Trimethylamine-N-oxide (TMAO) and trimethylamine (TMA) are gut microbiota-derived metabolites, and both are known uraemic toxins that are implicated in CKD, atherosclerosis, colorectal cancer and cardiovascular risk. Therefore, the detection and quantification of TMAO, which is a metabolite from gut microbes, are important for the diagnosis of diseases such as atherosclerosis, thrombosis and colorectal cancer. In this study, a new “colour-switch” method that is based on the combination of a plasma separation pad/absorption pad and polyallylamine hydrochloride-capped manganese dioxide (PAH@MnO2 ) nanozyme was developed for the direct quantitative detection of TMAO in whole blood without blood sample pretreatment. As a proof of concept, a limit of quantitation (LOQ) of less than 6.7 µM for TMAO was obtained with a wide linear quantification range from 15.6 to 500 µM through quantitative analysis, thereby suggesting potential clinical applications in blood TMAO monitoring for CKD patients.
AB - The gut microbiota plays a critical role in chronic kidney disease (CKD) and hypertension. Trimethylamine-N-oxide (TMAO) and trimethylamine (TMA) are gut microbiota-derived metabolites, and both are known uraemic toxins that are implicated in CKD, atherosclerosis, colorectal cancer and cardiovascular risk. Therefore, the detection and quantification of TMAO, which is a metabolite from gut microbes, are important for the diagnosis of diseases such as atherosclerosis, thrombosis and colorectal cancer. In this study, a new “colour-switch” method that is based on the combination of a plasma separation pad/absorption pad and polyallylamine hydrochloride-capped manganese dioxide (PAH@MnO2 ) nanozyme was developed for the direct quantitative detection of TMAO in whole blood without blood sample pretreatment. As a proof of concept, a limit of quantitation (LOQ) of less than 6.7 µM for TMAO was obtained with a wide linear quantification range from 15.6 to 500 µM through quantitative analysis, thereby suggesting potential clinical applications in blood TMAO monitoring for CKD patients.
UR - http://www.scopus.com/inward/record.url?scp=85116789119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116789119&partnerID=8YFLogxK
U2 - 10.3390/bios11090339
DO - 10.3390/bios11090339
M3 - Article
C2 - 34562929
AN - SCOPUS:85116789119
SN - 2079-6374
VL - 11
JO - Biosensors
JF - Biosensors
IS - 9
M1 - 339
ER -